A systematic review of the cost and cost-effectiveness studies of proton radiotherapy

Cancer

Volumn 122, Issue 10, 2016, Pages 1483-1501

  Verma, Vivek ^a   Mishra, Mark V ^b   Mehta, Minesh P ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; health care economics; operational costs; proton radiation therapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; BRAIN TUMOR; BREAST CANCER; CARDIOTOXICITY; CHILDHOOD CANCER; CONFORMAL RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DYSPHAGIA; ELECTRON THERAPY; ESOPHAGUS CANCER; EYE ENUCLEATION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; ION THERAPY; MEDICARE; MUCOSAL DISEASE; NON SMALL CELL LUNG CANCER; PARTIAL BODY RADIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; RADIATION HAZARD; REIMBURSEMENT; REVIEW; SKULL BASE TUMOR; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; UROGENITAL TRACT DISEASE; UVEA MELANOMA; WATCHFUL WAITING; XEROSTOMIA; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; NEOPLASMS; PROCEDURES; PROSTATIC NEOPLASMS;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; PROTON THERAPY;

EID: 84957555573     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29882     Document Type: Review

References (86)

1. Particle Therapy Co-Operative Group. Particle Therapy Centers. Available at: http://www.ptcog.ch/. Accessed July 13, 2015.
2. Pearlstein KA, Chen RC,. Comparing dosimetric, morbidity, quality of life, and cancer control outcomes after 3D conformal, intensity-modulated, and proton radiation therapy for prostate cancer. Semin Radiat Oncol. 2013; 23: 182-190.
3. Merchant TE,. Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol. 2013; 23: 97-108.
4. Combs SE, Laperriere N, Brada M,. Clinical controversies: proton radiation therapy for brain and skull base tumors. Semin Radiat Oncol. 2013; 23: 120-126.
5. Alonso-Basanta M, Lustig RA, Kennedy DW,. Proton beam therapy in skull base pathology. Otolaryngol Clin North Am. 2011; 44: 1173-1183.
6. Kao WH, Shen YL, Hong JH,. What are the potential benefits of using proton therapy in Taiwanese cancer patients? Biomed J. 2015; 38: 391-398.
7. Lukens JN, Lin A, Hahn SM,. Proton therapy for head and neck cancer. Curr Opin Oncol. 2015; 27: 165-171.
8. Emanuel EJ, Pearson SD,. It costs more, but is it worth more? New York Times. January 2, 2012;1A. Available at: http://opinionator.blogs.nytimes.com/2012/01/02/it-costs-more-but-is-it-worth-more/?-r=0. Accessed May 27, 2015.
9. Miller RC, Van Houten H, Foote RL, et al., Understanding the characteristics and types of adult and pediatric cancers treated with proton beam radiation therapy in a population of 88 million commercially insured patients [abstract]. Int J Radiat Oncol Biol Phys. 2014; 90: S64. Abstract 135.
10. Elnahal SM, Kerstjens J, Helsper RS, et al., Proton beam radiotherapy and accountable care: the challenges ahead [serial online]. Int J Radiat Oncol Biol Phys. 2013; 85: e165-e172.
11. Kerstjens J, Johnstone PA,. Proton therapy expansion under current United States reimbursement models. Int J Radiat Oncol Biol Phys. 2014; 89: 235-240.
12. Lievens Y, Pijls-Johannesma M,. Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol. 2013; 23: 134-141.
13. Chen AB,. Comparative effectiveness research in radiation oncology: assessing technology. Semin Radiat Oncol. 2014; 24: 25-34.
14. Mohan R, Bortfeld T,. Proton therapy: clinical gains through current and future treatment programs. Front Radiat Ther Oncol. 2011; 43: 440-464.
15. Mansur DB,. Incorporating a compact proton therapy unit into an existing National Cancer Institute-designated comprehensive cancer center. Expert Rev Anticancer Ther. 2014; 14: 1001-1005.
16. Moher D, Liberati A, Tetzlaff J, et al., Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Int J Surg. 2010; 8: 336-341.
17. Peeters A, Grutters JPC, Pijls-Johannesma M, et al., How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons, and photons. Radiother Oncol. 2010; 95: 45-53.
18. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B,. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005; 44: 850-861.
19. Konski A, Speier W, Hanlon A, Beck JR, Pollack A,. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007; 25: 3603-3608.
20. Aizer AA, Gu X, Chen M-H, et al., Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015; 13: 61-68.
21. Parthan A, Pruttivarasin N, Davies N, et al., Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated radiation therapy for localized prostate cancer [serial online]. Front Oncol. 2012; 2: 81.
22. Yu JB, Soulos PR, Herrin J, et al., Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105: 25-32.
23. Goyal RK, Meyer A-M, Sheets NC, et al., Cost-utility of proton therapy in the treatment of localized prostate cancer [abstract]. J Clin Oncol 2012; S30. Abstract e15184.
24. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B,. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother Oncol. 2005; 75: 179-185.
25. Taghian AG, Kozak KR, Katz A, et al., Accelerated partial breast irradiation using proton beams: initial dosimetric experience. Int J Radiat Oncol Biol Phys. 2006; 65: 1404-1410.
26. Ovalle V, Strom EA, Godby J, et al., Proton beam partial breast irradiation for early stage breast cancer: a not-so-costly alternative. Presented at: Particle Therapy Co-Operative Group of North America 1st Annual Meeting; October 27-29, 2014; Houston, TX.
27. Vargo JA, Verma V, Kim H, et al., Extended (5-year) outcomes of accelerated partial breast irradiation using MammoSite balloon brachytherapy: patterns of failure, patient selection, and dosimetric correlates for late toxicity. Int J Radiat Oncol Biol Phys. 2014; 88: 285-291. doi: 10.1016/j.ijrobp.2013.05.039.
28. Grutters JP, Pijls-Johannesma M, De Ruysscher D, et al., The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010; 36: 468-476.
29. Verma V,. Lung cancer: Implementing lung-cancer screening-oncological 'grey areas '. Nat Rev Clin Oncol. 2015; 12: 256-257.
30. Verma V,. Stereotactic Radiotherapy Versus Surgery for Early-Stage Operable Lung Cancer: More Questions Than Answers. J Natl Compr Canc Netw. 2015; 13: 1293-1295.
31. Verma V, Beriwal S,. Medicare Approves Coverage for Lung Cancer Screening: The Case for Symptomatic Screening. JAMA Oncol. 2015; 1: 1027-1028.
32. Verma V, Zhen W,. Treatment Costs of Early-Stage Lung Cancers Detected by Low-Dose Computed Tomography Screening. Int J Radiat Oncol Biol Phys. 2015; 93: 207-208.
33. Lievens Y, Verhaeghe N, De Neve W, et al., Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium? J Thorac Oncol. 2013; 8 (suppl 2): S839-S840.
34. Ramaekers BL, Grutters JP, Pijls-Johannesma M, Lambin P, Joore MA, Langendijk JA,. Protons in head-and-neck cancer: bridging the gap of evidence. Int J Radiat Oncol Biol Phys. 2013; 85: 1282-1288.
35. Verma V, Liu J, Eschen L, et al., Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients. Radiat Oncol. 2015; 10 (1): 8. doi: 10.1186/s13014-014-0314-3.
36. Frank SJ, Rosenthal DI, Ang K, et al., Gastrostomy tubes decrease by over 50% with intensity-modulated proton therapy (IMPT) during the treatment of oropharyngeal cancer patients: a case-control study [abstract]. Int J Radiat Oncol Biol Phys. 2013; 87: S144. Abstract 354.
37. Holliday E, Garden AS, Fuller CD, et al., Gastrostomy tube rates decrease by over 50% in patients with nasopharyngeal cancer treated with intensity-modulated proton therapy (IMPT): a case-control study [abstract]. Int J Radiat Oncol Biol Phys. 2014; 90: S528. Abstract 2805.
38. Thaker NG, Agarwal A, Kuban DA, et al., How can we decrease the cost of proton therapy? Presented at: Particle Therapy Co-Operative Group of North America 2nd Annual Meeting; May 18-23, 2015; San Diego, CA.
39. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B,. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer. 2005; 103: 793-801.
40. Mailhot Vega RB, Kim J, Bussiere M, et al., Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer. 2013; 119: 4299-4307.
41. Hirano E, Fuji H, Onoe T, et al., Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood. J Radiat Res. 2014; 55: 320-327.
42. Mailhot Vega R, Kim J, Hollander A, et al., Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015; 121: 1694-1702.
43. Verma V, Beethe AB, LeRiger M, et al., Anesthesia complications of pediatric radiation therapy. Pract Radiat Oncol. 2015. pii: S1879-8500(15)00394-X. doi: 10.1016/j.prro.2015.10.018.
44. Mouw KW, Sethi RV, Yeap BY, et al., Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys. 2014; 90: 863-869.
45. Bishop AJ, Greenfield B, Mahajan A, et al., Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 2014; 90: 354-361.
46. Yock TI, Bhat S, Szymonifka J, et al., Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol. 2014; 113: 89-94.
47. Greenberger BA, Pulsifer MB, Ebb DH, et al., Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014; 89: 1060-1068.
48. McGovern SL, Okcu MF, Munsell MF, et al., Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. Int J Radiat Oncol Biol Phys. 2014; 90: 1143-1152.
49. Ladra MM, Szymonifka JD, Mahajan A, et al., Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol. 2014; 32: 3762-3770.
50. Mizumoto M, Oshiro Y, Takizawa D, et al., Proton beam therapy for pediatric patients with ependymoma. Pediatr Int. 2015; 57: 567-571.
51. Lucas JT Jr, Ladra MM, MacDonald SM, et al., Proton therapy for pediatric and adolescent esthesioneuroblastoma. Pediatr Blood Cancer. 2015; 62; 1523-1528.
52. Chuong M, Bhooshan N, Allen P, et al., A multi-institutional analysis of acute toxicity after neoadjuvant chemoradiation using photons or protons in trimodality esophageal cancer patients. Presented at: Particle Therapy Co-Operative Group of North America 2nd Annual Meeting; May 18-23, 2015; San Diego, CA.
53. Chuong MD Hallemeier CL, Jabbour SK, et al., Improving Outcomes for Esophageal Cancer using Proton Beam Therapy Int. J Radiat Oncol Biol Phys. 2015;doi: 10.1016/j.ijrobp.2015.11.043.
54. Moriarty JP, Borah BJ, Foote RL, Pulido JS, Shah ND,. Cost-effectiveness of proton beam therapy for intraocular melanoma [serial online]. PLoS One. 2015; 10: e0127814.
55. Wlodarczyk A, Jaworska E, Budasz-Swiderska M,. Clinical and cost-effectiveness of proton beam radiotherapy for eye cancer: a systematic review [serial online]. Value Health. 2012; 15: A411.
56. Wang Z, Nabhan M, Schild SE, et al., Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 86: 18-26.
57. Badiyan SN, Rao RC, Apicelli AJ, et al., Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy. Int J Radiat Oncol Biol Phys. 2014; 88: 801-805. doi: 10.1016/j.ijrobp.2013.12.014.
58. Mishra KK, Quivey JM, Daftari IK, et al., Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. Int J Radiat Oncol Biol Phys. 2015; 92: 376-383.
59. Char DH, Kroll SH, Phillips TL, Quivey JM,. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. Ophthalmology. 2002; 109: 1850-1854.
60. Weinstein MC, Siegel JE, Gold MR, et al., Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276: 1253-1258.
61. Mitin T, Zietman AL,. Promise and pitfalls of heavy-particle therapy. J Clin Oncol. 2014; 32: 2855-2863.
62. Dvorak T, Wazer DE,. Evaluation of potential proton therapy utilization in a market-based environment. J Am Coll Radiol. 2010; 7: 522-528.
63. Dvorak T, Fitzek MM, Wazer DE,. Utilization of proton therapy: evidence-based, market-driven, or something in between? Am J Clin Oncol. 2013; 36: 192-196.
64. Richard P, Phillips M, Zeng J, et al., Developing a cost-effectiveness model for comparing radiation modalities for stage III NSCLC. Presented at: Particle Therapy Co-Operative Group of North America 1st Annual Meeting; October 27-29, 2014; Houston, TX.
65. Ubel PA, Hirth RA, Chernew ME, et al., What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 1637-1641.
66. Neumann PJ, Cohen JT, Weinstein MC,. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371: 796-797.
67. Rucinski A, Bauer J, Campbell P, et al., Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HIT [serial online]. Radiat Oncol. 2013; 8: 134.
68. Polf JC, Chuong M, Mehta M,. Novel proton beam arrangements for prostate cancer using in vivo range verification may significantly reduce the risk of high grade rectal toxicities. Presented at: Particle Therapy Co-Operative Group of North America 2nd Annual Meeting; May 18-23, 2015; San Diego, CA.
69. Darby SC, Ewertz M, McGale P, et al., Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368: 987-998.
70. Mast ME, Vredeveld EJ, Credoe HM, et al., Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. Breast Cancer Res Treat. 2014; 148: 33-39.
71. Shah C, Khan A, Arthur D, et al., Cancer Management Controversy: Regional Nodal Irradiation: Examining the Clinical Implications of Randomized Trials. Am J Clin Oncol. 2015 Nov 20. [Epub ahead of print] PMID 26600011.
72. Bradley JD, Paulus R, Komaki R, et al., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015; 16: 187-199.
73. Radiation Therapy Oncology Group (RTOG). RTOG 1308 Protocol. Available at: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1308. Accessed May 5, 2015.
74. Liao Z, Tucker SL, Gomez D, et al., Heart and lung radiation and overall survival in non-small cell lung cancer patients after chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2012; 84: S578. Abstract 2957.
75. US National Institutes of Health (NIH). Image-guided adaptive conformal photon versus proton therapy. Available at: https://clinicaltrials.gov/ct2/show/NCT00915005. Accessed May 5, 2015.
76. US National Institutes of Health (NIH). Study of hypo-fractionated proton radiation for low risk prostate cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT01230866. Accessed May 5, 2015.
77. Loeffler JS, Durante M,. Charged particle therapy-optimization, challenges, and future directions. Nat Rev Clin Oncol. 2013; 10: 411-424.
78. Grunder HA, Leeman CW,. Present and future sources of protons and heavy ions. Int J Radiat Oncol Biol Phys. 1977; 3: 71-80.
79. Suit H,. The Gray Lecture 2001: coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002; 53: 798-809.
80. van de Water S, Kooy HM, Heijmen BJ, Hoogeman MS,. Shortening delivery times of intensity modulated proton therapy by reducing proton energy layers during treatment plan optimization. Int J Radiat Oncol Biol Phys. 2015; 92: 460-468.
81. Klein EE, Bloch C, Zheng Y, Low DA,. Acceptance testing for the Monarch-250 proton radiotherapy unit. Int J Radiat Oncol Biol Phys. 2010; 78: S807-S807.
82. Westerly D, Plimpton S, Mo X, Miften M, Kavanagh B, Liu A,. Proton energy requirements for a dedicated pediatric treatment machine [abstract]. Int J Radiat Oncol Biol Phys. 2013; 87: S603-S604. Abstract 3048.
83. Estabrook NC, Hoene TA, McDonald MW,. Quantifying the optimum number of proton fields in treatment of midline tumors using a marginal cost analysis [abstract]. Int J Radiat Oncol Biol Phys. 2014; 90: S329. Abstract 2283
84. Johnstone PA, Kerstjens J, Richard H,. Proton facility economics: the importance of "simple" treatments. J Am Coll Radiol. 2012; 9: 560-563.
85. Goitein M, Jermann M,. The relative costs of proton and x-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003; 15: S37-S50.
86. Jarosek S, Elliott S, Virnig BA,. Proton beam radiotherapy in the US Medicare population: growth in use between 2006 and 2009: data points 10.2012 May 7. In: Data Points Publication Series. Rockville, MD: US Agency for Healthcare Research and Quality; 2011. Available at: http://www.ncbi.nlm.nih.gov/books/NBK97147/. Accessed September 30, 2015.